1234

Video interview re Pegasys supply

Haematologist Dr Cecily Forsyth and MPN AA advocate Nathalie Cook OAM have prepared an explanatory video for patients about the current Australian Pegasys supply. The video addresses the current and future supply issues and outlines strategies for patients and their haematologists to minimise any…
Read more

Pegasys supply update as of May 2025

The MPN AA has been advised of some very encouraging news about the Pegasys supply in Australia into the future. For details, please see the attached letter from the Australian supplier, Echo Therapeutics. Letter-to-Clinicians Patients and HCPs -Update-on-Pegasys®-supply-Australia-May-2025. …
Read more

“Sentry” myelofibrosis phase 3 clinical trial recruiting in Australia

An international clinical trial for myelofibrosis patients is currently in phase 3 and is actively enrolling in almost 150 sites across the world. The MPN AA has been asked to raise awareness because there are trial sites in Australia (see below).  If you have myelofibrosis and think it might be relevant…
Read more

Interferons in the treatment of myeloproliferative neoplasms

The MPNAA has just become aware of this extensive article about interferon, written by US haematologists and published in 2024 in Therapeutic Advances in Hematology. As so many more MPN patients are now being treated with interferon, we have copied the abstract as well as a link to the full article…
Read more

PBAC has recommended ruxolitinib be listed on the PBS for PV

We are thrilled to advise that the Pharmaceutical Benefits Committee (PBAC) at its March meeting has recommended that ruxolitinib (jakavi) be listed on the Pharmaceutical Benefits Scheme (PBS) for adult polycythemia vera patients who are resistant to or intolerant of hydroxycarbamide (hydroxyurea). This…
Read more

Momelotinib (OMJJARA) now on PBS

The MPN AA is delighted to advise that the Australian government has now approved the inclusion of momelotinib, now known as OMJJARA, onto the Pharmaceutical Benefits Scheme (PBS). Momelotinib was originally developed in Melbourne.  A short news item about its approval is HERE. What is momelotinib…
Read more

Welcome to the MPN Alliance Australia website

MPN stands for Myeloproliferative Neoplasms which are a group of rare chronic blood cancers.

The MPN Alliance Australia, (MPN AA) is run by MPN patients for MPN patients and their families. We all give of our time voluntarily.

MPN patient quality of life is central to everything we do. MPN Alliance Australia aims for these pages to assist patients and families to find support and relevant up to date information related to myeloproliferative neoplasms. This site acts as a portal to comprehensive evidence-based disease information.

We also provide external links to disease-specific articles and other information from Australian and international researchers and clinicians, and MPN organisations.

MPN Alliance Australia welcomes your feedback as we aim to support you as best we can. Please send us a message if you would like to share ideas with us to improve our site.

Share to:
Translate »